FDA Grants AP Status for Succinylcholine Chloride ANDA217873
The FDA has granted approval status (AP) for ANDA217873, a generic formulation of Succinylcholine Chloride by STERISCIENCE.
Published: June 23, 2026
Updated: June 23, 2026
Author: Humanexa Intelligence
Therapeutic area: Anesthesia / Neuromuscular Blocker
Asset: STERISCIENCE
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
STERISCIENCE
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of STERISCIENCE's generic Succinylcholine Chloride introduces a new competitor in the neuromuscular blocker market. This could lead to increased price competition and impact market share for existing products in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies of STERISCIENCE following this approval.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.